Navigation Links
Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Date:9/10/2012

SUNNYVALE, Calif. and SEATTLE, Sept. 10, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today presented positive data from its randomized, double-blind Phase 2a clinical study of CLP1001.  In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo.   

Data from the Phase 2a study were presented by Barry M. Massie, M.D., Professor, University of California, San Francisco, President of the Heart Failure Society of America and member of Sorbent's Medical Advisory Board, during the Late-Breaking News Symposium at the Heart Failure Society of America 16th Annual Scientific Meeting in Seattle, Washington.  

"The results of this clinical study suggest that CLP1001 may provide important benefits in addressing the signs and symptoms of heart failure," said Dr. Massie.  "Specifically, the reduction of dyspnea and improved physical functionality among patients dosed with CLP1001 are associated with a better quality of life in heart failure patients already on standard guideline recommended medications."

"Heart failure symptoms are generally debilitating – in spite of currently available therapies.  The positive findings from our Phase 2a clinical trial indicate that CLP1001 may improve patient outcomes," said Howard C. Dittrich, M.D., F.A.C.C., Sorbent's Chief Medical Officer.  "We look forward to working closely with the clinical community on additional clinical studies where we plan to measure the effects of CLP10001 on the physical functionality and overall quality of life of heart failure patients when administered in combination with standard medications for heart failure."

About the Phase 2a Study and Reported Clinical Results

The double-blind, randomized, parallel, placebo-controlled study examined the effe
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
3. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
4. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Creekridge Capital, an independent vendor-focused ... vendors so far in 2014 to their portfolio ... are from both the healthcare and technology industries. ... well-known multi-national companies. Each of these new vendors ... products including: standard leasing products, subscription solutions, a ...
(Date:7/23/2014)... 2014  When it comes to welcoming our new robot ... roll out the red carpet. Healthcare is one ... 9000-like robots into our human sphere. With healthcare concerns top ... need to apply new technologies to help with old problems. ... robotics is expected to increase from $1.7 billion now to ...
(Date:7/23/2014)... , July 23, 2014  Researchers from the North ... calcium elevates calcium levels too high, 1 ... health problems. Women close to menopause are ... D to prevent diseases such as osteoporosis, to which ... that women determine how much calcium they typically get ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Women Taking Too Much Calcium Create Health Risk 2
(Date:7/23/2014)... Home Care Assistance Calgary , North America’s ... to announce the next installment in its renowned Healthy ... of health and wellness-related fields. The upcoming webinar will ... Kriseman, and will cover the most common causes of ... more self-aware. In particular, Nancy will discuss mindfulness and ...
(Date:7/23/2014)... (HealthDay News) -- Regularly checking the pulse of a ... "Screening pulse is the method of choice for ... who have never had a stroke. Our study shows ... way to identify people who might need more thorough ... Dr. Bernd Kallmunzer, of Erlangen University in Germany. ...
(Date:7/23/2014)... Institute of Biomedical Imaging and Bioengineering will host its ... 30, 2014 on the NIH campus. There will be ... wide breadth of NIBIB-funded research. , WHO: ... Microbial Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, ... for Nerve Imaging during Surgery, ...
(Date:7/23/2014)... July 23, 2014 Global Cardio Care, ... Enhanced External Counterpulsation (EECP), is celebrating the 100th ... therapy at the health center. , Weber has ... Since receiving ongoing EECP therapy since 1999, he no ... Soulati, CEO of Global Cardio Care, introduced the ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a ... other behaviors on the autistic spectrum, as well as ... of mental impairment and the most common cause of ... California, Riverside have published a study that ... FXS. Appearing online today (July 23) in the ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... The following is a,statement from the Trust for America,s ... major health crisis because the United States does not,have ... Americans are uninsured;, Tens of millions of Americans ... $2 trillion a year on medical care, more than,any ...
... have done it again!, SAN DIEGO, Dec. 14 ... Young -- The Owner,s Manual for,Extending Your Warranty, lived up ... Diet, both New York Times #1 best-sellers. Within days,of its ... and,Barnes & Noble.com. Within just a few weeks, it became ...
... Dec. 14 Following is a statement,by Linda ... Products,Association (CHPA), regarding the recommendations of the U.S. ... phenylephrine:, "Phenylephrine 10 mg is safe when ... effective for nasal decongestion in multiple clinical trials.,Today, ...
... more than 8 years of follow-up, older women taking ... Dec. 14 (HealthDay News) -- The aromatase inhibitor drug ... it comes to preventing recurrences of hormone-receptor-positive breast cancers ... was stopped, women taking Arimidex still saw a benefit, ...
... Veridex, LLC, a,Johnson & Johnson company, is pleased ... Lymph Node (BLN) Assay one of the top ten,medical ... of the magazine, available today, TIME,states: "Surgeons now have ... With GeneSearch(TM) BLN Assay, TIME goes on to say, ...
... Indiana Plan Combines Personal Responsibility and Public,Dollars, ... announced the approval of a Medicaid waiver that ... innovative health care proposal giving,approximately 120,000 low-income, uninsured ... waiver, the state will be able to begin,accepting ...
Cached Medicine News:Health News:TFAH Board of Directors Issues Statement on U.S. Health Care Crisis 2Health News:YOU: Staying Young Fourth New York Times Best-Seller for RealAge Test Creator Dr. Michael Roizen! 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 2Health News:Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 2Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 3Health News:TIME Magazine Names GeneSearch(TM) One of the Top 10 Medical Breakthroughs in 2007 4Health News:HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers 2
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
... is the Bard Kugel Patch, which is constructed ... two layers create a positioning pocket, which is ... position. On the other side is a barrier ... "memory recoil ring," which causes the patch to ...
... patch repair is a minimally invasive, tension-free ... small 4-6 cm incision and requires minimal ... through an open, anterior approach that can ... Modified Kugel patch is a self-expanding polypropylene ...
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
Medicine Products: